Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILO phase 3 trial of MEK162 versus physician's choice chemotherapy in recurrent low-grade serous ovarian cancer
NL-OMON45111Phase 3Recruiting
- Sponsor
- Array BioPharma
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of binimetinib in Serous Papillary Cystadenocarcinoma, fallopian tube serous adenocarcinoma (FTC) and serous peritoneal carcinoma (PPSC) (2 arms), sponsored by Array BioPharma. Primary endpoint: Progression-free survival. Started Nov 2014; status: recruiting.
02
Drugs
binimetinib
03
Conditions
Serous Papillary Cystadenocarcinomafallopian tube serous adenocarcinoma (FTC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on NL-OMON45111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45111.